As AstraZeneca takes steps to reintroduce the EGFR-targeted NSCLC drug in the US, Qiagen will develop a tissue-based molecular CDx to accompany the launch.
The scientific organizations are revisiting the topic of molecular testing for lung cancer patients just a year and a half after releasing the initial guidelines.
The company, whose technology enables the selective amplification of mutant DNA, will use the financing to ramp up its commercialization work and build its product portfolio.
New survival data suggest that patients with del19 mutations should receive Gilotrif as their top option and that researchers should no longer clump different EGFR-mutated subpopulations together in research, lead study investigator Lecia Sequist said.
Originally published Sept. 25.
NEW YORK (GenomeWeb) – The National Cancer Institute this week kicked off its exceptional responders program, in which researchers will sequence tumor tissue from patients who have had an outlier response to investigational treatments.
NEW YORK (GenomeWeb) – The recent lawsuit filed by Esoterix Genetic Laboratories against Qiagen over an alleged breached licensing agreement covering EGFR testing may be a message to other labs who have sold tests without a license.
NEW YORK (GenomeWeb) — Researchers from several European institutions working with AstraZeneca have published a study demonstrating that measuring EGFR mutations from circulating tumor DNA compares favorably to tissue-based EGFR mutation status.
NEW YORK (GenomeWeb) – LabCorp subsidiary Esoterix Genetic Laboratories is suing Qiagen in a US district court alleging that Qiagen breached a licensing agreement between the companies regarding EGFR genetic testing by offering it for commercial research and diagnostic purposes ahead of US Food a
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
